Fonds Santé Diabète - CERITD

What Fonds Santé Diabète - CERITD does

Fonds Santé Diabète - CERITD is a French non-profit association (loi du 1er juillet 1901), founded in 2006 and recognized as serving public utility, headquartered at Bioparc Génopole in Évry. The organization operates a hybrid model that combines clinical diabetes care with applied research under a single structure, with the explicit intent of accelerating translation of research findings into patient treatment. Its clinical arm delivers insulin pump initiation, artificial pancreas management, dietary support, and 24/7 on-call nurse support to type 1 diabetes patients (adults and, more recently, pediatric and adolescent cohorts), with services reimbursed at 100% by French national health insurance.

CERITD's research portfolio centers on automated insulin delivery, exercise and stress management for glycemic control, telemedicine for diabetic foot ulcers, and predictive risk modeling for type 2 diabetes in at-risk families. Its signature technological achievement is the DBLG1 hybrid closed-loop artificial pancreas system — developed in partnership with CEA-LETI starting in 2011 — which combines continuous glucose monitoring, insulin pump therapy, and algorithmic control software to autonomously adjust insulin dosing in real time. The system obtained CE marking in November 2018 for adults, with subsequent extension to pediatric populations, and has been clinically validated through publications in The Lancet Digital Health (2019, 2022) and Diabetes Obesity and Metabolism (2015). CERITD co-founded Diabeloop in 2014 as the commercial spin-off responsible for manufacturing, regulatory compliance, and distribution, and remains its majority shareholder.

The business model rests on two principal revenue streams: voluntary charitable donations to the endowment fund Fonds Santé Diabète (eligible for a 66% French tax deduction and collected via SMS, check, online portal, and recurring direct debit), and clinical care fees reimbursed through the French healthcare system. Additional funding derives from EU research grants (Horizon Europe) and industrial partners. The organization does not disclose financial figures, headcount, or donor concentration. Beyond Diabeloop, CERITD maintains a research network spanning 15 national sites and partnerships with Université Paris-Saclay, the University of Hannover, Centre Hospitalier Sud Francilien, MSD, and VitalAire.

Name

Fonds Santé Diabète - CERITD

Legal name

CERITD - Centre d'Études et de Recherches pour l'Intensification du Traitement du Diabète

Website

https://fondssantediabete.org

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

CERITD is a French non-profit (founded 2006, Évry) that combines clinical diabetes care with applied research, developing the DBLG1 closed-loop artificial pancreas system commercialized via majority-owned spin-off Diabeloop and funded primarily through charitable donations and French health-insurance reimbursement.

Ownership category

akta.pro rank

Product category

Diabetes Care and Research Services

NAICS

Voluntary Health Organizations (813212), Health Care and Social Assistance (62), Scientific Research and Development Services (5417)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industries

Type 1 Diabetes Care (HLAKADAB), Endocrinology & Diabetes Telemedicine Platforms (HLALAGAD), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Diabetes Education & Insulin Management (Home-Based) (HSABACAJ)

Keywords

• Diabetes research
• Clinical diabetes care
• Artificial pancreas systems
• Insulin pump therapy
• Telemedicine diabetes

Headquarters

HQ city

Évry

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Charitable Donations: The organization operates as a charitable fonds de dotation (endowment fund) and nonprofit association. Revenue is generated entirely through voluntary donations from the public, including one-time donations via SMS, check, or online payment, as well as recurring monthly direct debits. Donations benefit from a 66% French tax deduction, making them fiscally attractive to donors.
2. Healthcare / Clinical Care Services: CERITD provides clinical care to patients with diabetes through its team of doctors, nurses, dietitians, and specialists. Services include insulin pump initiation, patient training, artificial pancreas management, and remote follow-up. The organization is recognized as serving public utility and benefits from the French healthcare system reimbursement framework (covered at 100% for eligible patients).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

CERITD provides clinical care to diabetes patients through a multidisciplinary team of doctors, nurses, dietitians, and specialists, including insulin pump initiation, artificial pancreas management, and 24/7 remote follow-up. The organization conducts translational research on diabetes treatment, developing proprietary technologies such as the DBLG1 artificial pancreas (commercialized via Diabeloop), the DIABRASPORT exercise algorithm, and the TELEPIED telemedicine system for diabetic foot ulcers. The Fonds Santé Diabète endowment fund collects tax-deductible donations to finance research and care programs.

Differentiator

Problem solved

Functional benefit

Brands

• Diabeloop DBLG1: Hybrid closed-loop insulin delivery system for type 1 diabetes patients
• Diabeloop DBL4T
• DIABRASPORT
• TELEPIED
• EPISTRESS
• Programme Descendance

Products and services

• Diabetes Clinical Care Services Comprehensive clinical care for diabetes patients delivered by a multidisciplinary team of doctors, nurses, dietitians, and specialists. Includes insulin pump initiation, patient training, artificial pancreas management, and remote follow-up. Services are covered at 100% by French national health insurance for eligible patients.
• DBLG1 Artificial Pancreas System Hybrid closed-loop insulin delivery system that automatically adjusts insulin based on real-time and predicted blood glucose levels. Developed in partnership with CEA-LETI and commercialized via Diabeloop (majority-owned spin-off). Clinical evidence published in The Lancet Digital Health (2019, 2022).
• DIABRASPORT Exercise Management Algorithm Algorithm for managing hypoglycemia risk during aerobic exercise in type 1 diabetes patients on insulin pump therapy. Prevents hypoglycemia during and after physical activity.
• TELEPIED Telemedicine System Remote monitoring and management system for diabetic foot ulcers using a specialist nurse acting via telemedicine delegation to a non-specialist home nurse. Reduces mean re-hospitalization days by half.
• EPISTRESS Stressometer Tool Online survey tool to assess the impact of stress on glycemic balance in type 1 diabetes patients. Used in EPISTRESS 1, EPISTRESS 2 national studies, and EVASTRESS real-life studies. Identified 4 patient stress profiles affecting glycemic balance.
• Descendance Risk Prediction Program Family-based program for early risk identification of type 2 diabetes, targeting non-diabetic subjects from families with diabetes across two successive generations. Uses a predictive risk equation derived from clinical data, dietary habits, and family genetics to enable early targeted prevention.
• DBL4T Closed-Loop System for Adolescents Closed-loop insulin delivery system adapted specifically for adolescents aged 12-18 with type 1 diabetes. Developed as part of the Diabeloop product line commercialized by CERITD's majority-owned spin-off.

Quantifiable outcome

• Reduction of mean re-hospitalization days by 50% through TELEPIED telemedicine management of diabetic foot ulcers
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• DiabeloopcoreStrategic or Co-development Partner · 1 January 2014Diabeloop is the commercial spin-off company co-founded by CERITD, of which CERITD remains the majority shareholder. Diabeloop commercializes the DBLG1 artificial pancreas system that originated from CERITD's research with CEA-LETI. CERITD continues as a clinical research partner and major shareholder. The partnership includes ongoing clinical studies (SP12 observatory, DBL4T teen study) and technology co-development.
• CEA-LETI (Laboratoire d'Électronique et de Technologie de l'Information)coreStrategic or Co-development Partner · 1 January 2011CEA-LETI is a leading international institute in microelectronics and micro/nanotechnologies. In 2011, CERITD launched the artificial pancreas 'Diabeloop Project' in partnership with CEA-LETI. This three-year project developed the patient database and first algorithm set, resulting in the DBLG1 prototype in 2014. CEA-LETI provided core technological expertise in microelectronics that enabled the closed-loop system's sensor and control architecture.
• Centre Hospitalier Sud Francilien (CHSF)minorStrategic or Co-development PartnerListed among organizations that trust and work with CERITD/Fonds Santé Diabète, appearing in the 'Ceux qui nous font confiance' (Those who trust us) logo section on the main website.
• Université Paris-Saclay / UPSaclay (Université Paris-Sud)minorStrategic or Co-development PartnerListed among partners supporting CERITD/Fonds Santé Diabète. The Genopole campus in Evry, where CERITD is located, is affiliated with Université Paris-Saclay, a major research university in the Paris region.
• Université de Hannover (Hanover)minorStrategic or Co-development PartnerListed among trusted partners of CERITD. The partnership relates to international academic collaboration in diabetes research.
• MSD (Merck Sharp & Dohme)minorOthersPharmaceutical company listed as a supporter/trusted partner of CERITD. Nature of partnership not detailed but appears in the logo section of the main website.
• VitalAireminorOthersHealthcare equipment/durable medical goods provider listed among CERITD's trusted partners, likely involved in providing or supporting insulin pump and diabetes management equipment.
• GenopoleminorStrategic or Co-development PartnerGenopole is the biopark/campus in Evry where CERITD is headquartered. It supports biotech and healthcare innovation companies and research organizations, providing infrastructure and ecosystem support for CERITD's research activities.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• EOFlow: EOFlow (acquired by Medtronic) developed the EOPatch tubeless patch pump with an AID algorithm. Emerging AID player comparable to Diabeloop in the closed-loop and patch-pump category for type 1 diabetes management.
• Beta Bionics: Beta Bionics developed the iLet bionic pancreas, a dual-hormone closed-loop system for type 1 diabetes. Emerging AID player directly comparable to DBLG1 in algorithmic closed-loop approach and target patient population.

Others

• JDRF (Juvenile Diabetes Research Foundation): JDRF is a global voluntary health organization funding type 1 diabetes research. Comparable to CERITD/Fonds Santé Diabète as a nonprofit research funding and advocacy entity focused exclusively on type 1 diabetes, though with a U.S./global scope and no direct clinical care operations.
• Joslin Diabetes Center: Joslin is an academic research and clinical care institution affiliated with Harvard Medical School, combining diabetes research with direct patient care. Comparable to CERITD's hybrid research-clinical model, though Joslin is larger and operates in the U.S. healthcare system.
• INSERM (Institut national de la santé et de la recherche médicale): INSERM is France's national institute for health and medical research, comparable to CERITD's research mission within the French public-sector research ecosystem. Adjacent rather than directly competing — INSERM funds and operates research units while CERITD is a disease-specific nonprofit combining research with patient care.
• American Diabetes Association: The American Diabetes Association is a voluntary health organization supporting diabetes research, advocacy, and education. Comparable to Fonds Santé Diabète as a nonprofit funding and awareness entity, though broader in scope (type 1 and type 2) and without direct patient care delivery.

Direct peers

• Insulet Corporation: Insulet's Omnipod 5 automated insulin delivery system is a tubeless patch-pump AID platform competing directly with Diabeloop DBLG1. Directly comparable in target patient segment (type 1 diabetes) and product category (hybrid closed-loop AID).
• Tandem Diabetes Care: Tandem's t:slim X2 with Control-IQ is a leading commercial hybrid closed-loop AID system. Directly comparable as a competing AID platform serving type 1 diabetes patients with integrated CGM and pump control algorithms.
• Diabeloop: Diabeloop is the commercial spin-off co-founded by CERITD (majority shareholder) that develops and commercializes the DBLG1 closed-loop artificial pancreas. Directly comparable because it is the commercial vehicle for the core technology originated from CERITD's research and shares algorithmic IP and clinical pipeline.

Broad incumbents

• Medtronic Diabetes: Medtronic's MiniMed 670G and 780G are the most established commercial AID systems globally with FDA approval. Broad incumbent comparable to CERITD/Diabeloop because it competes in the same AID category but operates across the broader diabetes device portfolio including pumps, CGMs, and analytics.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/Ceritd_
• Facebookfacebook.com/Ceritd-446343822099199/?ref=pages_you_manage
• LinkedInlinkedin.com/company/fsd-ceritd
• Instagraminstagram.com/fsd_ceritd
• TikToktiktok.com/@ceritd_fsd

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fonds Santé Diabète - CERITD